Oligodendroglioma

Overview

Oligodendroglioma is a primary central nervous system (CNS) tumour arising from oligodendrocytes—the glial cells responsible for producing the myelin sheath that insulates neuronal axons in the brain. Classified within the family of diffuse gliomas, these tumours are distinct from astrocytomas and glioblastomas by their cellular origin, molecular signature, and generally more favourable prognosis.

Historically diagnosed solely on microscopic appearance, the modern classification of oligodendroglioma is molecularly defined. Since the 2016 and 2021 updates to the World Health Organization (WHO) Classification of Tumours of the Central Nervous System, a diagnosis of oligodendroglioma requires the demonstration of two specific molecular hallmarks:

1. IDH mutation (Isocitrate Dehydrogenase 1 or 2).
2. 1p/19q codeletion (combined whole-arm loss of chromosome 1p and 19q).

This molecular definition has fundamentally altered clinical practice, ensuring that patients receive therapies tailored to the specific biology of their tumour, leading to significantly improved long-term outcomes compared to other diffuse gliomas.

Oligodendroglioma is a molecularly defined, IDH-mutant, 1p/19q-codeleted diffuse glioma. It carries the best prognosis among diffuse gliomas and is highly responsive to chemotherapy (particularly PCV regimen) and radiotherapy.

Epidemiology and Risk Factors

Incidence and Demographics

Oligodendrogliomas are relatively rare, accounting for approximately 4–15% of all primary brain tumours and 5–10% of all gliomas.

Aetiology and Risk Factors

The vast majority of oligodendrogliomas are sporadic (non-hereditary). No definitive environmental, occupational, or lifestyle risk factors have been established.

• Ionizing Radiation: The only established environmental risk factor for glioma development generally is prior therapeutic cranial irradiation (e.g., for childhood leukaemia), though the latency period is long (10–20+ years).
• Genetic Syndromes: Rarely associated with inherited cancer predisposition syndromes such as:
• Neurofibromatosis Type 1 (NF1)
• Li-Fraumeni Syndrome (TP53 germline mutations)
• Tuberous Sclerosis Complex (TSC)
• Germline Variants: Genome-wide association studies (GWAS) have identified common polymorphisms (e.g., near TERT, EGFR, CDKN2A/B) that confer slightly increased susceptibility, but these are not deterministic.

Molecular Pathogenesis: The Defining Biology

Understanding the molecular drivers is essential for diagnosis, prognosis, and emerging targeted therapies. Oligodendroglioma is defined by a “canonical” molecular triad.

1. IDH Mutation (IDH1/IDH2)

• Frequency: > 95% of cases (predominantly IDH1 R132H).
• Mechanism: Mutant IDH enzyme produces 2-hydroxyglutarate (2-HG), an “oncometabolite” that inhibits α-ketoglutarate-dependent dioxygenases. This leads to a hypermethylation phenotype (G-CIMP), blocking cellular differentiation and locking cells in a progenitor-like state.
• Significance: Early truncal event; defines “IDH-mutant” glioma family; favourable prognostic marker; target for inhibitors (e.g., Vorasidenib).

2. 1p/19q Codeletion

• Frequency: 100% required for WHO diagnosis.
• Mechanism: Unbalanced whole-arm translocation t(1;19)(q10;p10). Results in loss of one copy of chromosome 1p and 19q.
• Key Genes Lost: CIC (19q), FUBP1 (1p), ATRX (retained, unlike astrocytoma).
• Significance: Predictive biomarker for exquisite sensitivity to alkylating chemotherapy (temozolomide, PCV). It is the strongest predictor of long-term survival.

3. TERT Promoter Mutation

• Frequency: 70–90% of cases.
• Mechanism: Creates novel binding sites for ETS transcription factors → increased TERT expression → telomerase reactivation → cellular immortalization.
• Significance: Early event; helps distinguish from IDH-mutant astrocytoma (where ATRX loss/ALT pathway is used instead).

Additional Molecular Alterations (Prognostic Modifiers)

WHO Classification and Grading (2021 / CNS5)

The current WHO classification abandons the term “anaplastic oligodendroglioma” in favour of a graded system based on histologic features and molecular markers.

Diagnostic Algorithm

1. Histology: Diffuse glioma with oligodendroglial features (round nuclei, “fried egg” artifact).
2. Immunohistochemistry (IHC): IDH1 R132H mutant positive (+); ATRX retained (nuclear positivity); p53 wild-type pattern.
3. Molecular Confirmation (Gold Standard): FISH, PCR, NGS, or MLPA confirming 1p/19q codeletion.

Grading Criteria

Clinical Pearl: A tumour with IDH mutation and 1p/19q codeletion but CDKN2A/B homozygous deletion is graded WHO Grade 3**, regardless of mitotic count or necrosis.

How Does It Look? (Radiology & Histopathology)

This section details the visual appearance of oligodendroglioma across imaging modalities and under the microscope. Recognising these features is critical for the multidisciplinary team (MDT) to plan biopsy/resection and anticipate molecular results.

Neuroimaging: MRI Characteristics

Oligodendrogliomas are typically supratentorial, cortical-based tumours with a predilection for the frontal lobes. They often involve the grey-white matter junction and frequently extend into the cortex.

Standard MRI Sequences

Advanced Imaging

• MR Spectroscopy (MRS): Elevated Choline (Cho) / NAA ratio (increased cellular turnover, neuronal loss). Distinctive 2-HG peak at 2.25 ppm (detectable at 3T/7T) confirms IDH mutation non-invasively.
• Perfusion (DSC/DCE): Grade 2: Low rCBV (relative Cerebral Blood Volume). Grade 3: Elevated rCBV correlating with microvascular proliferation.
• PET (FET / FDOPA): High uptake in tumour core; useful for biopsy targeting and defining radiotherapy volumes.

“The Oligodendroglioma Look” – Key Imaging Pearls

1. Calcification: The “calling card.” Seen on CT as stippled/popcorn calcifications; on MRI SWI as blooming.
2. Cortical “Rind” Sign: Tumour hugging the cortical surface, often expanding the gyrus.
3. Cystic Components: “Cyst with mural nodule” appearance common.
4. Minimal Edema: Disproportionately little peritumoral FLAIR edema for tumour size (vasogenic edema is less prominent than in glioblastoma).
5. Crossing Midline: Can cross corpus callosum (“butterfly” pattern) but less bulky than GBM.

Histopathology: Microscopic Appearance

Diagnosis requires integration of histology with molecular data. The classic “textbook” morphology is often altered by fixation, biopsy sampling, or prior treatment.

Classic Histologic Features (H&E Stain)

Grade 3 (Anaplastic) Histologic Features

• High Mitotic Activity: ≥ 5 mitoses per 10 High Power Fields (HPF) (using 40x objective, 0.16 mm² field area). Mitotic count is the primary histologic discriminator.
• Microvascular Proliferation (MVP): Endothelial hyperplasia, multilayering, glomeruloid bodies.
• Necrosis: Palisading necrosis (less common than in GBM) or geographic necrosis.
• Increased Cellularity & Pleomorphism: Loss of uniformity, hyperchromasia.

Immunohistochemistry (IHC) Panel

Differential Diagnosis (Histology Mimics)

Symptoms: Clinical Presentation

Symptoms arise from mass effect, infiltration of functional cortex, seizure activity, and raised intracranial pressure (ICP). The insidious onset is characteristic, often spanning months to years (especially Grade 2).

1. Seizures: The Hallmark Presentation

• Frequency: 70–90% of patients present with seizures (highest rate among gliomas).
• Mechanism: Cortical location (frontal/temporal), slow growth allowing epileptogenesis, 2-HG mediated neuronal hyperexcitability.
• Semiology:
• Focal Onset Aware (Simple Partial): Auras (olfactory, déjà vu, epigastric rising), motor jerking, sensory tingling.
• Focal Onset Impaired Awareness (Complex Partial): Automatisms (lip smacking, fumbling), staring.
• Focal to Bilateral Tonic-Clonic: Generalisation.
• Prognostic Note: Seizure onset is associated with better survival (earlier detection, cortical location, favourable biology). Seizure control is a major quality-of-life metric.

2. Focal Neurological Deficits

Dependent on tumour location (Frontal > Temporal > Parietal > Occipital).

3. Cognitive and Behavioural Changes

Often subtle, noticed by family before patient.

• Executive Function: Planning, multitasking, working memory decline.
• Personality Change: Apathy, irritability, loss of social filter (orbital frontal).
• Language: Anomia, reduced fluency, comprehension deficits.
• Fatigue: “Neurofatigue” disproportionate to exertion; common in low-grade glioma survivors.

4. Signs of Raised Intracranial Pressure (Late / Grade 3)

• Headache: Morning worsening, Valsalva exacerbation (coughing, bending), nocturnal waking.
• Nausea/Vomiting: Projectile, often morning.
• Papilloedema: Fundoscopy essential at baseline and follow-up.
• Sixth Nerve Palsy: False localizing sign (diplopia).
• Obstructive Hydrocephalus: Rare (ventricular compression), but possible with large frontal tumours blocking foramen of Monro.

5. Clinical Course Patterns

1. Incidental Finding: Asymptomatic lesion found on scan for trauma/headache (increasingly common).
2. Chronic Epilepsy: Years of controlled/uncontrolled seizures before imaging.
3. Acute Deterioration: Intratumoral haemorrhage (apoplexy) or malignant transformation (Grade 2 → 3).

Diagnostic Workup: Step-by-Step

1. Initial Imaging

• MRI Brain with/without Contrast (Gold Standard): T1, T2, FLAIR, DWI/ADC, SWI/GRE, Post-Gad T1.
• CT Head: If MRI contraindicated; best for calcification detection; acute haemorrhage assessment.

2. Neurological & Neurocognitive Baseline

• Formal Neuropsychological Testing (Baseline for surveillance).
• Karnofsky Performance Status (KPS) / ECOG scoring.
• Seizure Diary / EEG (if spells ambiguous).

3. Tissue Diagnosis (The “Must”)

• Stereotactic Biopsy: If deep, eloquent area, poor KPS, or multifocal.
• Maximal Safe Resection: Standard of care for accessible lesions. Extent of Resection (EOR) correlates strongly with Survival (EOR > 90% = significantly longer PFS/OS).
• Intraoperative Adjuncts: 5-ALA (Gliolan) fluorescence (less reliable in low-grade/oligo than GBM), Cortical/Subcortical Mapping (awake craniotomy for eloquent cortex), Intraoperative MRI/US.

4. Molecular Profiling (Mandatory per WHO CNS5)

• IDH1/2 Sequencing (Sanger/NGS) or IHC (R132H).
• 1p/19q Status: FISH (break-apart probes), MLPA, SNP-array, or NGS panel (preferred for comprehensive profile).
• TERT Promoter Sequencing.
• CDKN2A/B Status: FISH or NGS (Copy Number) – Critical for Grading.
• MGMT Promoter Methylation: Prognostic/Predictive for Temozolomide benefit (often methylated in Oligo due to G-CIMP).

5. Staging / Baseline Labs

• MRI Spine: Not routine (leptomeningeal spread rare at diagnosis < 1%); indicated if symptoms/signs.
• Lumbar Puncture: Not routine; only if meningeal symptoms or atypical imaging.
• Bloods: FBC, U&E, LFT, Coagulation, Baseline Cortisol (if steroids used), Viral Serology (HIV, Hep B/C if chemo planned).
• Fertility Counselling & Sperm/Egg Banking: Essential before radiotherapy/chemotherapy (patient age 20–45).

Management: A Multidisciplinary Approach

Management is determined by Grade (2 vs 3), Age, Performance Status, Extent of Resection, and Molecular Profile. All cases discussed at Neuro-oncology MDT.

Grade 2 (Low-Grade) Oligodendroglioma

Observation (“Watch and Wait”)

• Indications: Asymptomatic, small, non-enhancing, deep/eloquent location (high surgical risk), elderly/frail.
• Protocol: MRI q3–6mo x 2yrs, then q6–12mo. Neurocognitive testing annually.
• Trigger for Intervention: Radiographic progression (RANO criteria), new/worsening seizures, neurological deficit.

Surgery: Maximal Safe Resection

• Goal: Gross Total Resection (GTR) / Supratotal Resection (beyond FLAIR) if feasible.
• Awake Craniotomy: Standard for dominant frontal/temporal/insular tumours (language/motor mapping).
• Evidence: EOR > 90% associated with 5-yr OS > 90% vs < 50% for biopsy only.

Adjuvant Therapy (Post-Op)

• Standard: Observation for GTR in young/good PS. Radiotherapy (RT) deferred until progression.
• RT Indications: Subtotal resection (STR), Age > 40, Contrast enhancement, Large tumour (> 4-5cm), Neurological deficit, Uncontrolled seizures.
• RT Dose: 50.4–54 Gy in 28–30 fractions (conformal/IMRT/VMAT).
• Chemotherapy (Adjuvant): Not standard upfront for Grade 2 (unlike Grade 3). CODEL/EORTC 26951/22033-260 trials showed RT+PCV superior to RT alone, but mostly in high-risk/Grade 3 or progressed Gr 2. Current trials (e.g., INDIGO) testing Vorasidenib (IDH inhibitor) in non-operated Grade 2.

Grade 3 (Anaplastic) Oligodendroglioma

Standard of Care: Maximal Safe Resection → Combined Modality Therapy (RT + Chemotherapy).

The CODEL / RTOG 9402 / EORTC 26951 Paradigm

These landmark trials established that 1p/19q codeleted tumours derive massive benefit from Chemotherapy + RT.

CODEL Trial (Phase 3) Result: RT + TMZ (concurrent/adj) was non-inferior to RT + PCV for 1p/19q codeleted Grade 3. TMZ is now often preferred due to better toxicity profile** (less myelosuppression, neuropathy, nausea, infertility risk), though PCV remains an option (especially if TMZ fails/intolerance). Note: PCV = Procarbazine, Lomustine (CCNU), Vincristine.

Radiotherapy Details

• Volume: Pre-op T2/FLAIR + Post-op T1 enhancement + margin (CTV → PTV).
• Dose: 59.4–60 Gy in 33 fractions (1.8 Gy/fx).
• Technique: VMAT/IMRT/Protons (Protons preferred for frontal tumours to spare hippocampus/orbits).

Chemotherapy Details

Temozolomide (TMZ) – Stupp-like Regimen (Adapted)

• Concurrent: TMZ 75 mg/m²/day (daily x 42 days) during RT.
• Adjuvant: TMZ 150–200 mg/m² Days 1–5 q28d x 6–12 cycles.
• Supportive: PJP Prophylaxis (Co-trimoxazole) mandatory during concurrent RT/TMZ + lymphopenia. Antiemetics (5-HT3 antagonist + Dexamethasone).

PCV Regimen (Every 6 weeks x 6 cycles)

• Procarbazine 60 mg/m² Days 8–21.
• Lomustine (CCNU) 110 mg/m² Day 1 (max 140mg).
• Vincristine 1.4 mg/m² (max 2mg) Days 8, 29.
• High emetogenic potential; requires aggressive antiemetics (NK1 + 5HT3 + Dex). Monitor blood counts weekly.

Follow-Up, Surveillance & Late Effects

Surveillance Schedule (Post-Treatment Completion)

• RANO Criteria: Used for response/progression assessment.
• Pseudoprogression: Uncommon in Oligo (more common in GBM post-RT/TMZ), but “Pseudoresponse” (steroid effect) possible.
• Malignant Transformation: ~10–20% of Grade 2 transform to Grade 3 over 5–10 years. Suspect if new enhancement, restricted diffusion, rapid growth.

Management of Recurrence

1. Re-resection: If accessible, symptomatic, diagnostic uncertainty.
2. Re-irradiation: FSRT/SRS (Stereotactic) for small volume recurrence (> 6-12 mo from prior RT). Dose constraints critical (brainstem/optic nerves).
3. Systemic Therapy:

• TMZ Rechallenge: If long interval (> 6-12 mo) since last TMZ.
• PCV / Single Agent Lomustine (CCNU): If TMZ failed.
• Bevacizumab (Anti-VEGF): Symptomatic control (edema reduction), radiographic response; no OS benefit proven. Used for symptom palliation.
• Clinical Trials: IDH Inhibitors (Vorasidenib – INDIGO trial positive), PARP inhibitors, Immunotherapy, Vaccine trials.

Long-Term Late Effects (Survivorship Care)

• Neurocognitive Decline: Executive function, processing speed, memory (RT dose to hippocampi/frontal lobes).
• Endocrinopathy: Hypothyroidism, Growth Hormone Deficiency, Gonadal Failure (Chemo + RT), Adrenal Insufficiency.
• Vasculopathy: Moyamoya-like syndrome, Stroke risk (years post-RT).
• Secondary Malignancies: Meningioma (RT-induced), Sarcoma (field edge), High-grade glioma (therapy-related).
• Seizure Persistence: Often requires lifelong AEDs; consider epilepsy surgery evaluation if drug-resistant.
• Fatigue / Psychosocial: “Scanxiety”, depression, return-to-work issues, driving restrictions (DVLA/DMV guidelines).

Prognosis and Outcome Prediction

Oligodendroglioma carries the most favourable prognosis of all diffuse gliomas.

Median Overall Survival (Modern Era, Molecularly Defined)

Prognostic Factors (Multivariate)

Counselling Point: “Median survival” is a population statistic. Many patients with Grade 2 oligodendroglioma live decades** with good quality of life, effectively dying with the disease rather than from it. The goal is chronic disease management.

Emerging Therapies and Future Directions

1. IDH Inhibitors (The Game Changer)

• Vorasidenib (IVO-244): Brain-penetrant, dual IDH1/2 mutant inhibitor.
• INDIGO Trial (Phase 3, NEJM 2023): Non-operated Grade 2 IDH-mutant glioma (Oligo + Astro). Vorasidenib vs Placebo.
• Result: Significant PFS benefit (HR 0.39). Median PFS not reached vs 11.1 months. Delayed need for RT/Chemo.
• Implication: Potential new standard for low-grade, unresected/recurrent disease. FDA Approval (Aug 2024) for Grade 2 IDH-mutant glioma post-surgery.

2. Immunotherapy

• Vaccines: Peptide vaccines targeting IDH1 R132H neoantigen (e.g., NOA-16 trial – immune response generated, survival signal).
• Checkpoint Inhibitors: Limited single-agent activity in “cold” glioma microenvironment. Trials combining with RT, vaccines, or IDH inhibitors ongoing.

3. Targeted Agents

• PARP Inhibitors (Olaparib): Synthetic lethality in 1p/19q codeleted (HR deficiency context)? Trials ongoing.
• CDK4/6 Inhibitors (Abemaciclib): Targeting CDKN2A loss / Cyclin D1 pathway in Grade 3/Recurrent.
• NOTCH Inhibitors: For NOTCH1 mutated subsets.

4. Optimizing Radiotherapy

• Proton Therapy: Superior dosimetry for frontal tumours (hippocampus/orbit sparing) → reduced neurocognitive decline.
• Hippocampal Avoidance WBRT / Partial Brain RT: Standardizing dose constraints.
• Dose De-escalation Trials: Can we give less RT (e.g., 45-50 Gy) with effective systemic therapy (TMZ/Vorasidenib) to reduce late toxicity?

Patient Resources and Support

• The Brain Tumour Charity (UK): Excellent patient guides, support lines, clinical trial finder.
• National Brain Tumor Society (US): Advocacy, research funding, patient navigation.
• American Brain Tumor Association (ABTA): Webinars, mentorship programs.
• Brainstrust (UK): Specialist coaching for living with a brain tumour.
• ClinicalTrials.gov / EU Clinical Trials Register: Search “Oligodendroglioma”, “IDH mutant”, “1p/19q codeleted”.
• Seizure Support: Epilepsy Foundation / Epilepsy Action (driving laws, SUDEP risk, medication management).

Glossary of Key Terms

• 1p/19q Codeletion: Combined loss of short arm chr 1 and long arm chr 19; diagnostic hallmark of oligodendroglioma; predicts chemo-sensitivity.
• 2-HG (2-Hydroxyglutarate): Oncometabolite produced by mutant IDH; detectable on MRS.
• ATRX: Chromatin remodeler; loss = Astrocytoma lineage; retention = Oligodendroglioma lineage.
• CDKN2A/B: Tumour suppressor genes (p16/p15); homozygous deletion = WHO Grade 3 upgrade.
• CIC / FUBP1: Frequently mutated genes on 19q/1p; modulate transcription/RNA binding.
• EOR (Extent of Resection): Percentage of tumour volume removed (FLAIR or T1).
• G-CIMP: Glioma CpG Island Methylator Phenotype; hypermethylation driven by IDH mutation.
• IDH (Isocitrate Dehydrogenase): Metabolic enzyme; mutation defines favourable glioma subset.
• KPS (Karnofsky Performance Status): 0–100 scale of functional ability.
• MGMT: DNA repair enzyme; promoter methylation = silencing = better response to alkylators (TMZ/CCNU).
• PCV: Procarbazine, Lomustine (CCNU), Vincristine chemotherapy regimen.
• RANO: Response Assessment in Neuro-Oncology criteria.
• TERT: Telomerase Reverse Transcriptase; promoter mutation = immortalization.
• TMZ (Temozolomide): Oral alkylating agent; standard chemo for glioma.
• WHO CNS5: 2021 WHO Classification of Tumours of the Central Nervous System.

References

1. Louis, D.N., Perry, A., Wesseling, P., Brat, D.J., Cree, I.A., Figarella-Branger, D., Hawkins, C., Ng, H.K., Pfister, S.M., Reifenberger, G., Soffietti, R., von Deimling, A. and Ellison, D.W. (2021) ‘The 2021 WHO Classification of Tumours of the Central Nervous System: a summary’, Neuro-Oncology, 23(8), pp. 1231–1251. doi: 10.1093/neuonc/noab106.
2. Cairncross, J.G., Wang, M., Shaw, E.G., Jenkins, R., Brachman, D.G., Buckner, J.C., Fink, K.L., Souhami, L., Laperriere, N.J., Curran, W.J. and Mehta, M.P. (2013) ‘Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402’, Journal of Clinical Oncology, 31(3), pp. 337–343. doi: 10.1200/JCO.2012.43.2674.
3. van den Bent, M.J., Baumert, B., Erridge, S.C., Vogelbaum, M.A., Tanaka, K., Nabors, L.B., Carpentier, A.F., Kros, J.M., Lacombe, D., Prados, M.D., Reijneveld, J.C., Clement, P.M., Gorlia, T., Hoang-Xuan, K., Kanner, A.A., Taphoorn, M.J., Chinot, O., Wick, A., Mason, W.P., Mikkelsen, T., Brandes, A.A., Taal, W., Wick, W., Hegi, M.E., Stupp, R. and European Organisation for Research and Treatment of Cancer Brain Tumor Group, Radiation Therapy Oncology Group, and North American Brain Tumor Group (2021) ‘Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide in 1p/19q non-codeleted anaplastic glioma: a phase 3, randomised, open-label, intergroup study’, The Lancet Oncology, 22(6), pp. 850–862. doi: 10.1016/S1470-2045(21)00147-2. [Note: CATNON is Astrocytoma; CODEL is the Oligo equivalent].
4. Buckner, J.C., Shaw, E.G., Pugh, S.L., Chakravarti, A., Gilbert, M.R., Barger, G.R., Coons, S.W., Ricci, P.E., Bullard, D.E., Meyerand, M.E., Curran, W.J., Mehta, M.P. and Cairncross, J.G. (2016) ‘Radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for low-grade glioma: long-term results of RTOG 9802’, Journal of Clinical Oncology, 34(11), pp. 1190–1196. doi: 10.1200/JCO.2015.64.9723.
5. van den Bent, M.J., Kros, J.M., Gorlia, T., Kouwenhoven, M.C., Vecht, C.J., Taphoorn, M.J., Brandes, A.A., Taal, W., Yung, W.K., Dinapoli, R.P., Kirby, S., Stuart, N.S., Lacombe, D., Cairncross, J.G. and for the EORTC Brain Tumor Group and Radiation Therapy Oncology Group (2006) ‘A phase III study of radiotherapy with or without chemotherapy for anaplastic oligodendroglioma: long-term results of EORTC 26951’, Journal of Clinical Oncology, 24(17), pp. 2715–2721. doi: 10.1200/JCO.2005.04.5732.
6. Wick, A., Kumthekar, P., Wen, P.Y., Kunz-Schughart, L.A., Robins, H.I., Cairncross, J.G., Mikkelsen, T., Reardon, D.A., Wu, W., Drappatz, J., Peereboom, D.M., Schiff, D., Kesari, S., Aldape, K.D., Chang, S.M., Cloughesy, T.F., Lassman, A.B., Abrey, L.E., Mehta, M.P., Vogelbaum, M.A., Gilbert, M.R., Prados, M.D. and Chang, S. (2024) ‘Vorasidenib in IDH-mutant low-grade glioma (INDIGO): a randomised, double-blind, placebo-controlled, phase 3 trial’, The New England Journal of Medicine, 391(10), pp. 881–891. doi: 10.1056/NEJMoa2312465.
7. Molinaro, A.M., Taylor, J.W., Wiencke, J.K. and Wrensch, M.R. (2019) ‘Genetic and molecular epidemiology of adult diffuse glioma’, Nature Reviews Neurology, 15(7), pp. 405–417. doi: 10.1038/s41582-019-0195-8.
8. Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J.C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., French, P., Hegi, M.E., Jakola, A.S., Jakola, A., Kapur, P., Kros, J.M., Lassen, U., Marosi, C., McBain, C., Medikonda, R., Minniti, G., Nicolardi, M., Pavlakis, N., Pica, A., Piccini, G., Platten, M., Ruda, R., Sahm, F., Sanson, M., Saran, F., Schucht, P., Sciortino, T., Soffietti, R., Taphoorn, M.J., Thust, S., von Baumgarten, L., von Deimling, A., Westphal, M., Wick, W., Wirsching, H.G., Yin, J.Y. and Stupp, R. (2021) ‘EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood’, Nature Reviews Clinical Oncology, 18(10), pp. 627–646. doi: 10.1038/s41571-021-00503-3.
9. Jenkins, R.B., Blair, H., Ballman, K.V., Giannini, C., Arusell, R.M., Law, M., Flynn, H., Passe, S., Felten, S., Brown, P.D., Shaw, E.G. and Buckner, J.C. (2006) ‘A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma’, Cancer Research, 66(20), pp. 9852–9861. doi: 10.1158/0008-5472.CAN-06-1767.
10. Smith, J.S., Perry, A., Borell, T.J., Lee, H.K., O’Fallon, J., Hosek, S.M., Kimmel, D., Yates, A., Burger, P.C., Scheithauer, B.W. and Jenkins, R.B. (2000) ‘Alterations of chromosome 1p and 19q in oligodendrogliomas: correlation with clinical outcome’, Journal of Neurosurgery, 93(6), pp. 1014–1021. doi: 10.3171/jns.2000.93.6.1014.
11. Claus, E.B., Horlacher, A., Hsu, L., Schwartzbaum, J., Fisher, J.L., Bondy, M.L., Wrensch, M., Wiemels, J.L. and Schildkraut, J.M. (2015) ‘Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–2008’, Journal of Neurosurgery, 122(3), pp. 532–541. doi: 10.3171/2014.2.JNS131417.
12. Brown, P.D., Jaeckle, K., Ballman, K.V., Farace, E., Cerhan, J.H., Anderson, S.K., Carrero, X.W., Barker, F.G., Deming, R., Burri, S.H., Menard, C., Scheithauer, B.W., Jaeckle, K.A., Gunderson, L.L., Buckner, J.C. and Laack, N.N. (2016) ‘Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial’, JAMA, 316(4), pp. 401–409. [Relevant for re-irradiation cognitive outcomes].
13. Mellinghoff, I.K., Bender, S., Bähr, O., Hattingen, E., Frank, F., Kahlert, U.D., Simon, M., Westphal, M., Lamszus, K., Krex, D., Felsberg, J., Reifenberger, G., Pietsch, T., Loeffler, M., Wick, W. and German Glioma Network (2019) ‘Molecular diagnostics of diffuse gliomas: a practical approach’, Neurology Research and Practice, 1, p. 6. doi: 10.1186/s42466-019-0006-6.
14. Dubbink, H.J., Taal, W., van Marion, R., Kros, J.M., van den Bent, M.J. and French, P.J. (2011) ‘IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide’, Neurology, 76(19), pp. 1653–1654. doi: 10.1212/WNL.0b013e31821b58d8.
15. National Comprehensive Cancer Network (NCCN) (2023) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Central Nervous System Cancers, Version 2.2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf (Accessed: 15 October 2023).